• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Qingyu, ZHOU Jianping, HUO Meirong. Advances in the nanotechnology-based drug delivery systems of silymarin[J]. Journal of China Pharmaceutical University, 2015, 46(3): 376-384. DOI: 10.11665/j.issn.1000-5048.20150320
Citation: CHEN Qingyu, ZHOU Jianping, HUO Meirong. Advances in the nanotechnology-based drug delivery systems of silymarin[J]. Journal of China Pharmaceutical University, 2015, 46(3): 376-384. DOI: 10.11665/j.issn.1000-5048.20150320
shu

Advances in the nanotechnology-based drug delivery systems of silymarin

More Information
    Graphical Abstract
    • Abstract
  • Recent advances in nanotechnology have greatly facilitated the development of nanoparticle drug delivery system. The present work reviews recent literature on nanotechnology-based applications and developments of silymarin preparation. A variety of nanoparticle formulations have been extensively investigated to improve the absorption and bioavalability of silymarin, including: improving the drug dissolution signficantly(such as nanosuspensions, inclusion complex with β-cyclodextrins, self-emulsifying drug delivery systems, solid dispersions, micronization), promoting the permeability across cell membrane(such as complexation with phospholipids, nanostructured lipid carriers)and other methods(such as micelles, mesoporous silica nanoparticles, polyamidoamine dendrimers). The applications of nanoscience and nanotechnology can help to promote the further pharmaceutical development of silymarin.
    • FullText(HTML)
    • References (61)
  • [1]
    Kaur M,Agarwal R.Silymarin and epithelial cancer chemoprevention:how close we are to bedside[J]?Toxicol Appl Pharm,2007,224(3):350-359.
    [2]
    Milic N,Milosevic N,Suvajdzic L,et al.New therapeutic potentials of milk thistle(Silybum marianum)[J].Nat Prod Commun,2013,8(12):1801-1810.
    [3]
    Kawabata Y,Wada K,Nakatani M,et al.Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system:basic approaches and practical applications[J].Int J Pharm,2011,420(1):1-10.
    [4]
    Doane T, Burda C. Nanoparticle mediated non-covalent drug delivery[J].Adv Drug Deliv Rev,2013,65,(5):607-621.
    [5]
    Wang MQ,Zhang JX,Yuan ZM,et al.Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles[J].J Biomed Nanotechnol,2012,8(4):624-632.
    [6]
    Chen MW,Tan W,Wang SP,et al.Advances in the nanoparticle drug delivery systems of silymarin[J].J Chin Pharm Sci(中国药学杂志),2011,20(5):442-446.
    [7]
    He W,Lu Y,Qi JP,et al.Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs[J].Int J Pharm,2013,441(1):269-278.
    [8]
    Zhou JP,Huo MR.Advances on modern pharmaceutics[J].J China Pharm Univ(中国药科大学学报),2007,38(2):97-104.
    [9]
    Wang Y,Liu Z,Zhang D,et al.Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension[J].Colloid Surface B,2011,83(2):189-197.
    [10]
    Sievens-Figueroa L,Bhakay A,Jerez-Rozo J I,et al.Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications[J].Int J Pharm,2012,423(2):496-508.
    [11]
    Zhao XY,Wang GH,Zhang BX,et al.Preparation and characterization of lyophilized silymarin nanosuspensions[J].China J Chin Mater Med(中国中药杂志),2009,34(12):1503-1508.
    [12]
    Wang W,Zhao N,Luan LB,et al.Preparation of silybin nanosuspensions and their pharmacokinetics in rats[J].Anti Infect Pharm(抗感染药学),2009,6(3):153-157.
    [13]
    Wang Y,Zhang D,Liu Z,et al.In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery[J].Nanotechnology,2010,21(15):155104.
    [14]
    Xiao YY,Ping QN.Effects of borneol-β-cyclodextrin inclusion complex on the plasma and brain concentrations of tetramerhylpyrazine phosphate in mice[J].J China Pharm Univ(中国药科大学学报),2009,40(5):412-415.
    [15]
    Ghosh A,Biswas S,Ghosh T.Preparation and evaluation of silymarin β-cyclodextrin molecular inclusion complexes[J].J Young Pharm,2011,3(3):205-210.
    [16]
    Xiao L,Di SD,Zhao RS,et al.Bioavailability of silymarin glycol-β-cyclodextrin inclusion complex in rats[J].Chin J Hosp Pharm(中国医院药学杂志),2006,26(2):140-142.
    [17]
    Zhang YL,Wang X,Ma WW,et al.The optimization of metronidazole β-cyclodextrin inclusion complex preparation by orthogonal experimental design[J].Prog Mod Biomed(现代生物医学进展),2012,21(10):961-964.
    [18]
    Feng ZY,Hu RF,Sun YL,et al.Formula optimization of simvastatin self-emulsifying drug delivery system and its pharmacokinetics in Beagle dogs[J].J China Pharm Univ(中国药科大学学报),2009,40(2):131-134.
    [19]
    Niederquell A,Volker AC,Kuentz M.Introduction of diffusing wave spectroscopy to study self-emulsifying drug delivery systems with respect to liquid filling of capsules[J].Int J Pharm,2012,426(1):144-152.
    [20]
    Wei YH,Ye XL,Shang XJ,et al.Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system(S-SEDDS)[J].Colloid Surface A,2012,396(20):22-28.
    [21]
    McClements DJ.Nanoemulsions versus microemulsions:terminology,differences,and similarities[J].Soft Matter, 2012,8(6):1719-1729.
    [22]
    Al-Obaidi H,Lawrence MJ,Shah S,et al.Effect of drug-polymer interactions on the aqueous solubility of milled solid dispersions[J].Int J Pharm,2013,446(1):100-105.
    [23]
    Moes JJ, Koolen SLW, Huitema ADR, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel(ModraDoc001)[J].Int J Pharm,2011,420(2):244-250.
    [24]
    Wu JX, Yang M, van den Berg F, et al. Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability[J].Eur J Pharm Sci,2011,44(5):610-620.
    [25]
    Yao WW,Bai TC,Sun JP,et al.Thermodynamic properties for the system of silybin and poly(ethylene glycol)6000[J].Thermochim Acta,2005,437(1):17-20.
    [26]
    Qiu MF,Jia W,Li SS,et al.A new silymarin preparation based on solid dispersion technique[J].Adv Ther,2005,22(6):595-600.
    [27]
    Sun N,Zhang X,Lu Y,et al.In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating[J].Planta Med,2008,74(2):126-132.
    [28]
    Han X,Ghoroi C,To D,et al.Simultaneous micronization and surface modification for improvement of flow and dissolution of drug particles[J].Int J Pharm,2011,415(1):185-195.
    [29]
    Zhang ZB,Shen ZG,Wang JX,et al.Micronization of silybin by the emulsion solvent diffusion method[J].Int J Pharm,2009,376(1):116-122.
    [30]
    Di Pierro F,Callegari A,Carotenuto D,et al.Clinical efficacy,safety and tolerability of BIO-C(micronized Silymarin)as a galactagogue[J].Acta Biomed,2008,79(3):205-210.
    [31]
    Capasso R, Aviello G, Capasso F, et al. Silymarin BIO-C®,an extract from Silybum marianum fruits,induces hyperprolactinemia in intact female rats[J].Phytomedicine,2009,16(9):839-844.
    [32]
    Bombardelli E.Phytosome:new cosmetic delivery system[J].Boll Chim Farm,1991,130(11):431-438.
    [33]
    Tang XQ,Yang XL.Effect of breviscapine phosphatidylcholine complex in small intestine of rat[J].China J Chin Mater Med(中国中药杂志),2005,30(3):222-225.
    [34]
    Zhong YQ,Liu SK,Chen GS,et al.The status of bioavailability enhancement on silymarin[J].J Pharm Pract(药学实践杂志),2003,21(3):139-140.
    [35]
    Barzaghi N,Crema F,Gatti G,et al.Pharmacokinetic studies on IdB 1016,a silybin-phosphatidylcholine complex,in healthy human subjects[J].Eur J Drug Metab Pharmacokinet,1990,15(4):333-338.
    [36]
    Jiang B,Yin CH.Bioavailability enhancement of silybin-phosphatidylcholine complex in rabbits[J].Chin J Pharm(中国医药工业杂志),2002,33(12):598-600.
    [37]
    Xiao YY,Song YM,Chen ZP,et al.The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats[J].Int J Pharm,2006,307(1):77-82.
    [38]
    Han F,Liu HZ,Li SM.Advances in transdermal delivery of solid lipid nanoparticles and nanostructured lipid carriers[J].J Shenyang Pharm Univ(沈阳药科大学学报),2008,25(10):839-844.
    [39]
    Jia LJ,Zhang DR,Li ZY,et al.Preparation and characterization of silybin-loaded nanostructured lipid carriers[J].Drug Deliv,2010,17(1):11-18.
    [40]
    Jia LJ,Zhang DR,Li ZY,et al.b>(6):571-588.
    [41]
    Menjoge AR,Rinderknecht AL,Navath RS,et al.Transfer of PAMAM dendrimers across human placenta:prospects of its use as drug carrier during pregnancy[J].J Control Release,2011,150(3):326-338.structured lipid carriers for improved oral bioavailability of silymarin[J].J Biomater Appl,2014,28(6):887-896.
    [42]
    Souto EB,Almeida AJ,Müller RH.Lipid nanoparticles(SLN®,NLC®)for cutaneous drug delivery:structure,protection and skin effects[J].J Biomed Nanotechnol,2007,3(4):317-331.
    [43]
    Li PZ,Yang ZL,Yang KW,et al.Recent advances of multifunctional polymeric micelles[J].Chin J New Drugs(中国新药杂志),2008,17(3):199-202.
    [44]
    Maeda H,Wu J,Sawa T,et al.Tumor vascular permeability and the EPR effect in macromolecular therapeutics:a review[J].J Control Release,2000,65(1):271-284.
    [45]
    Wu Q,Huo MR,Zhou JP.Advances on novel drug delivery system[J].J China Pharm Univ(中国药科大学学报),2013,44(2):97-104.
    [46]
    Yang QX,Chen JM.Research on improving bioavailability of silymarin[J].J Pharm Pract(药学实践杂志),2010,28(3):164-166.
    [47]
    Zhang Y,Li X,Zhou Y,et al.Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid)micelles:preparation,in vitro and in vivo characterization and transport mechanism across the intestinal barrier[J].Mol Pharm,2010,7(4):1169-1182.
    [48]
    Xu XM,Zhu Y,Li Q,et al.Preparation of silymarin nanomicelles and their pharmacokinetics in rats[J].China Pharm J(中国药学杂志),2005,40(24):1874-1876.
    [49]
    Wu YP,Huo MR,Zhou JP.Preparation and in situ absorption in rat intestine of silymarin-loaded amphiphilic chitosan micelles[J].Acta Pharm Sin(药学学报),2009,44(6):651-657.
    [50]
    Li X,Huang Y,Chen X,et al.Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin[J].J Drug Target,2009,17(10):739-750.
    [51]
    Ren LX,Wang B.Preparation and characterization of carvedilol solid disperasions using hollow mesoporous silica nanoparticles[J].J China Pharm Univ(中国药科大学学报),2014,45(1):59-64.
    [52]
    Fu TM,Lu J,Guo LW,et al.Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials[J].J Nanosci Nanotechnol,2012,12(5):3997-4006.
    [53]
    Cao X,Deng WW,Fu M,et al.In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles[J].Int J Nanomed,2012,7:753-762.
    [54]
    Wang X,Teng ZG,Huang XY,et al.Advances in drug delivery systems for cancer diagnosis and therapy based on mesoporous silica nanoparticles[J].Acta Pharm Sin(药学学报),2013,48(1):8-13.
    [55]
    Tomalia DA,Hall M,Hedstrand DM.Starburst dendrimers.III.the importance of branch junction symmetry in the development of topological shell molecules[J].J Am Chem Soc,1987,109(5):1601-1603.
    [56]
    Pan SR,Cao DW,Yi W,et al.A biodegradable and serum-resistant gene delivery carrier composed of polyamidoamine-poly N,N-di-(2-aminoethyl)aminoethyl glutamine copolymer[J].Colloid Surface B,2013,104(1):294-302.
    [57]
    Dong ZQ,Katsumi H,Sakane T,et al.Effects of polyamidoamine(PAMAM)dendrimers on the nasal absorption of poorly absorbable drugs in rats[J].Int J Pharm,2010,393(1/2):245-253.
    [58]
    Kang R,Cao LZ.The status of polyamidoamine dendrimers nanostructure carriers applied to anti-tumor drugs[J].Foreign Med Sci(国外医学),2004,31(2):96-98.
    [59]
    Huang X,Wu ZH,Gao W,et al.Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin[J].Drug Dev Ind Pharm,2011,37(4):419-427.
    [60]
    Sadekar S,Ghandehari H.Transepithelial transport and toxicity of PAMAM dendrimers:implications for oral drug delivery[J].Adv Drug Deliv Rev,2012,64(6):571-588.
    [61]
    Menjoge AR,Rinderknecht AL,Navath RS,et al.Transfer of PAMAM dendrimers across human placenta:prospects of its use as drug carrier during pregnancy[J].J Control Release,2011,150(3):326-338.
    • Related Articles

  • Related Articles

    [1]GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
    [2]XIN Minhang, ZHANG Sanqi. Advances in PI3Kδ selective inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 503-510. DOI: 10.11665/j.issn.1000-5048.20160501
    [3]ZHU Kuiniu, WU Zhengfeng, JIANG Cuihua, CAO Lanjie, ZHANG Jian, YIN Zhiqi. Advances on hypoglycemic activity and mechanism of triterpenoids[J]. Journal of China Pharmaceutical University, 2015, 46(6): 764-770. DOI: 10.11665/j.issn.1000-5048.20150622
    [4]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [5]DENG Danni, TIAN Hong, YAO Wenbing. Advances in therapeutic B-cell vaccines against chronic diseases[J]. Journal of China Pharmaceutical University, 2013, 44(5): 470-475. DOI: 10.11665/j.issn.1000-5048.20130517
    [6]LIU Jinchuan, PENG Guizi, LU Zhijun, ZUO Lian. Advances of recombinant human follicle-stimulating hormone[J]. Journal of China Pharmaceutical University, 2013, 44(3): 283-288. DOI: 10.11665/j.issn.1000-5048.20130319
    [7]WANG Jing, ZHANG Hui-bin, ZHOU Jin-pei, LI Qing. Advances in new anti-tuberculosis targets and related drugs[J]. Journal of China Pharmaceutical University, 2012, 43(1): 1-8.
    [8]XU Si-sheng, ZHANG Hui-bin, ZHOU Jin-pei, HUANG Jian-jun. Advances of new antidiabetic drugs[J]. Journal of China Pharmaceutical University, 2011, 42(2): 97-106.
    [9]Advances in the research of factor Xa inhibitors[J]. Journal of China Pharmaceutical University, 2010, 41(2): 104-111.
    [10]Advances in Selective COX-2 Inhibitors[J]. Journal of China Pharmaceutical University, 2003, (3): 1-6.

Catalog

    Get Citation
    XML
    Article views (1558) PDF downloads (1402) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：282684

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return